Last reviewed · How we verify
Erythromycin A Carbonate (davercin)
Erythromycin A Carbonate (generic name: davercin) is a drug. It is currently in unknown development.
Erythromycin A Carbonate works by inhibiting bacterial protein synthesis.
Erythromycin A Carbonate, also known as Davercin, is a small molecule antibiotic. It is used to treat various bacterial infections, although its specific indications are not provided. The commercial status of Davercin is unknown, and it may be patented or generic. Key safety considerations include potential gastrointestinal side effects and interactions with other medications. Further information on its pharmacokinetics and safety profile is needed.
At a glance
| Generic name | davercin |
|---|---|
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like factories that make proteins. Bacteria are like tiny factories that also make proteins, but they can cause harm. Erythromycin A Carbonate stops these bacterial factories from making proteins, which ultimately kills the bacteria and treats the infection.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Erythromycin A Carbonate CI brief — competitive landscape report
- Erythromycin A Carbonate updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Erythromycin A Carbonate
What is Erythromycin A Carbonate?
How does Erythromycin A Carbonate work?
What is the generic name of Erythromycin A Carbonate?
What development phase is Erythromycin A Carbonate in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing